BioCentury | Oct 6, 2020
Product Development

Reversing the impact of COVID-19 on oncology clinical trials

...As more contract research organizations, such as Covance...
BioCentury | Mar 24, 2020
Product Development

March 23 COVID-19 roundup: Gilead looks to expand access to remdesivir, antiviral gains Orphan designation; plus N.Y.’s chloroquine trial, Celltrion and more

...from COVID-19 using a mobile phlebotomy service provided by Laboratory Corp. of America Holdings (NYSE:LH). Covance Inc....
BioCentury | Feb 25, 2020
Product Development

Europe ramps up response to COVID-19 outbreak

...NYSE:JNJ); Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK); Roche (SIX:ROG; OTCQX:RHHBY); Servier; Astellas Pharma Inc. (Tokyo:4503); Covance Inc....
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

...III trial to treat sickle cell disease in August (see “Next up for GlycoMimetics” ). Covance...
...develop immune profiling service with Fluidigm single-cell tech Laboratory Corp. of America Holdings (NYSE:LH) CRO Covance Inc....
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...which Bristol-Myers Squibb Co. (NYSE:BMY) is acquiring. Wagman is a veteran of Prometheus Laboratories Inc., Covance Inc....
BioCentury | Nov 16, 2018
Financial News

Neurology company Cadent emerges with $40M series B

...first CMO. He was senior medical director for clinical development services in neuroscience at the Covance Inc....
BioCentury | Nov 15, 2018
Financial News

Neurology company Cadent emerges with $40M series B

...first CMO. He was senior medical director for clinical development services in neuroscience at the Covance Inc....
BioCentury | Aug 4, 2017
Company News

LabCorp to acquire CRO Chiltern for $1.2B

...development, and complement Covance’s late-phase experience with Chiltern’s expertise in early clinical development. LabCorp acquired Covance...
...Slough, U.K. Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Business: Diagnostics, Supply/Service Alex Himes Chiltern International Ltd. Covance Inc. Laboratory...
BioCentury | Jul 31, 2017
Company News

LabCorp buying CRO Chiltern for $1.2B

...development, and complement Covance’s late-phase experience with Chiltern’s expertise in early clinical development. LabCorp acquired Covance...
...and expects 5-6.5% growth in 2017. LabCorp lost $1.16 to $158.91 on Monday. Alex Himes Chiltern International Ltd. Covance Inc. LabCorp Laboratory...
BioCentury | Jan 21, 2017
Tools & Techniques

Hopes in the machine

...this pathway causes a change in phenotypes,” he told BioCentury. In 2012, GNS partnered with Covance Inc....
...from the Covance partnership, but “we demonstrated that it was possible to do,” Hill said. Covance...
Items per page:
1 - 10 of 97
BioCentury | Oct 6, 2020
Product Development

Reversing the impact of COVID-19 on oncology clinical trials

...As more contract research organizations, such as Covance...
BioCentury | Mar 24, 2020
Product Development

March 23 COVID-19 roundup: Gilead looks to expand access to remdesivir, antiviral gains Orphan designation; plus N.Y.’s chloroquine trial, Celltrion and more

...from COVID-19 using a mobile phlebotomy service provided by Laboratory Corp. of America Holdings (NYSE:LH). Covance Inc....
BioCentury | Feb 25, 2020
Product Development

Europe ramps up response to COVID-19 outbreak

...NYSE:JNJ); Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK); Roche (SIX:ROG; OTCQX:RHHBY); Servier; Astellas Pharma Inc. (Tokyo:4503); Covance Inc....
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

...III trial to treat sickle cell disease in August (see “Next up for GlycoMimetics” ). Covance...
...develop immune profiling service with Fluidigm single-cell tech Laboratory Corp. of America Holdings (NYSE:LH) CRO Covance Inc....
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...which Bristol-Myers Squibb Co. (NYSE:BMY) is acquiring. Wagman is a veteran of Prometheus Laboratories Inc., Covance Inc....
BioCentury | Nov 16, 2018
Financial News

Neurology company Cadent emerges with $40M series B

...first CMO. He was senior medical director for clinical development services in neuroscience at the Covance Inc....
BioCentury | Nov 15, 2018
Financial News

Neurology company Cadent emerges with $40M series B

...first CMO. He was senior medical director for clinical development services in neuroscience at the Covance Inc....
BioCentury | Aug 4, 2017
Company News

LabCorp to acquire CRO Chiltern for $1.2B

...development, and complement Covance’s late-phase experience with Chiltern’s expertise in early clinical development. LabCorp acquired Covance...
...Slough, U.K. Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Business: Diagnostics, Supply/Service Alex Himes Chiltern International Ltd. Covance Inc. Laboratory...
BioCentury | Jul 31, 2017
Company News

LabCorp buying CRO Chiltern for $1.2B

...development, and complement Covance’s late-phase experience with Chiltern’s expertise in early clinical development. LabCorp acquired Covance...
...and expects 5-6.5% growth in 2017. LabCorp lost $1.16 to $158.91 on Monday. Alex Himes Chiltern International Ltd. Covance Inc. LabCorp Laboratory...
BioCentury | Jan 21, 2017
Tools & Techniques

Hopes in the machine

...this pathway causes a change in phenotypes,” he told BioCentury. In 2012, GNS partnered with Covance Inc....
...from the Covance partnership, but “we demonstrated that it was possible to do,” Hill said. Covance...
Items per page:
1 - 10 of 97